Allergan’s chronic dry eye drops will make patients shed more tears

Allergan has received approval from the FDA for Restasis, treatment to help patients with a type of Chronic Dry Eye make more of their own tears.

The FDA has approves Cyclosporine Ophthalmic Emulsion 0.05%, a preservative-free, multi-dose bottle offering the same preservative-free formulation of Restasis since the launch in 2003.

“Restasis multidose will be an important addition to the Allergan family of dry eye products, as it will enable healthcare providers to offer an additional option for those patients who may prefer their eye drops in a multi-dose bottle versus single-use vials,” said Neda Shamie, MD, fellowship-trained cornea  and cataract specialist, of Advanced Vision Care, of Los Angeles, Calif.

Allergan further says that Restasis multidose is designed with a patented unidirectional valve and air filter technology that eliminates the need for a preservative. The new multi-dose bottle uses less plastic than a package of single-use vials and will be available for the same price.

“Restasis multidosetm exemplifies Allergan’s commitment to innovation and customer responsiveness,” said David Nicholson, Chief R&D Officer at Allergan.  “Through our Open Science model, we drive to deliver advancements in highly engineered developments, such as the new multi-dose bottle.”, Nicholson added.